# Increasing Delta-9-Tetrahydrocannabinol (Δ-9-THC) Content in Herbal Cannabis Over Time: Systematic Review and Meta-Analysis

Fidelia Cascini[*,1], Carola Aiello[2] and GianLuca Di Tanna[3]

[1]*Istituto di Medicina Legale, Università Cattolica del S. Cuore, largo F. Vito, 1 00168 Roma, Italy*

[2]*Department of Informatics and Systemics, University 'La Sapienza', 00185 Rome, Italy*

[3]*Department of Public Health and Infectious Diseases, University "La Sapienza", 00185, Rome, Italy*

**Abstract:** *Aim*: The objective of this meta-analysis is to assess the data regarding changes in herbal cannabis potency over time (from 1970 to 2009).

*Methods*: Systematic searches of 17 electronic scientific databases identified studies on this topic, within which 21 case series studies satisfied our inclusion criteria of reporting the mean tetrahydrocannabinol (THC) value per number of samples per year. No language, publication date, publication type or status restrictions were imposed. The study selection and data extraction processes were performed independently but uniformly by two authors, included screening, determination of eligibility and inclusion of the eligible studies in the systematic review, and a meta-analysis of the results on THC content in herbal cannabis samples. We considered papers and not monographic scientific publications, rejecting all studies that were not focused on the subject of this review.

*Results*: Meta-analysis by year was performed on 21 studies containing 75 total mean THC observations from 1979 to 2009 using the random effects model. The results revealed much variability between studies. Further, there was a significant correlation between year and mean THC in herbal cannabis. The combined data indicated the correlation between year and mean THC in herbal cannabis, revealing a temporal trend of increasing potency (5% above the mean THC value in the Poisson regression analysis).

*Conclusions*: The results of the analysis suggest that there has been a recent and consistent increase in cannabis potency worldwide.

**Keywords:** Cannabis, marijuana, tetrahydrocannabinol, drug potency, drug efficacy, trend, THC content, THC concentration, meta-analysis.

## INTRODUCTION

The cannabis market is the largest illicit drug market in terms of the global spread of cultivation, volume of production and number of consumers [1].

There is great interest in the subject, sometimes linked with apprehension about increasing drug potency and its effects on human health, as revealed by newspapers [2-5], government reports [6, 7], and scientific publications [8-11] despite the scarce availability of reliable data; existing information on cannabis is fragmented, non-standardized and not always based on scientific evidence.

Published data concerning the diffusion of high potency cannabis varieties and the level of increase in potency are poor worldwide; further, new and successful cultivation methods – which allow selection, cloning and the stimulation of the best plant varieties – exist in the drug market alongside imported, traditional and low psychotropic subspecies [12]. There is variability within and between publications with regards to the sourcing, sampling and analytical approaches to herbal cannabis.

*Address correspondence to this author at the Istituto di Medicina Legale, Università Cattolica del S Cuore, largo F. Vito, 1 00168 Roma, Italy; Tel: +39 335 7011646; E-mail: f.cascini@rm.unicatt.it

Herbal cannabis consists of the dried flowering, fruiting tops and leaves of the cannabis plant [13]. The aim of this meta-analysis is to summarize published results concerning the Δ-9-tetrahydrocannabinol (THC) content of cannabis[1] in order to determine the temporal trend in mean THC content over the period 1970 - 2009.

## METHODS

The systematic review and meta-analysis shown here are new on this topic, even if a narrative review of nine publications has been published previously [14].

The sources used for guidance were the Cochrane Handbook [15] and the PRISMA guidelines [16].

[1]The *World Drug Report 2007,* United Nations Office on Drugs and Crime (available on http://www.unodc.org/unodc/en/data-and-analysis/WDR-2007.html) states that cannabis is produced for different end products:

- **Cannabis herb** comprises the flowering tops and leaves of the plant, which are smoked like tobacco using a variety of techniques. Depending on the region, cannabis herb is known under many different names, including 'marijuana, 'ganja', 'dagga', etc. A very potent form of cannabis herb is sinsemilla, the flowering tops of the unpollinated female plants.
- **Cannabis resin** consists of the secretions of the plant emitted in the flowering phase of its development. Depending on the region, cannabis resin is known as 'hashish' or as 'charas', etc.
- **Cannabis oil** (hashish oil) is an oily mixture resulting from extraction or distillation of the THC-rich parts of the cannabis plant.

1874-4737/12 $58.00+.00 

*Literature search* – A systematic literature search was carried out by consulting 17 electronic scientific databases including MEDLINE, TOXLINE, SCOPUS, The Cochrane Library, Web of Science, Directory of Open Access Journal; electronic editorial networks such as BMJ, Blackwell, Elsevier, Karger, Nature Publishing Group, Springer; electronic distributors such as OVID Journals and Swetswise; and governmental websites such as the UNODC (United Nations Office on Drugs and Crime) and the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). Additional searches included bibliographies of retrieved papers and direct contact with experts (Mahmoud Elsohly, USA; Emanuela Licata, Italy) who provided data on the number of samples seized per year and the mean THC content per year.

*Inclusion criteria* – We considered all studies that included quantification and recording of the THC content in herbal cannabis samples found on the illicit as well as on the licit drug market. No language, publication date, publication type or status restrictions were imposed. We also used the PICOS approach [2] to select studies according to the objective of this review to provide evidence about the increasing Δ-9-(THC) [3] content in herbal cannabis.

Herbal cannabis samples with a known THC content were the population of interest; there were no limits on plant variety, geographic origin, cultivation methods (i.e. outdoor or indoor; cloning or pollination), plant stage at harvesting, type or conservation status of the sample at the time of chemical analysis, or modes of sourcing samples (i.e. seized or freely sold).

*Study selection* – This process (see the flow diagram in Fig. **1**) was performed independently but uniformly by two authors, and included screening, determination of eligibility and inclusion of the eligible studies in the systematic review, and meta-analysis of the results on THC content in herbal cannabis samples.

We considered papers and not monographic scientific publications, rejecting all studies that were not focused on the subject of this review, such as those concerning the toxic effects of cannabinoids on humans and animals, synthetic cannabinoids and their pharmacological properties, genetic features of the cannabis plant, social issues and drug policy on cannabis.

We also excluded studies that completely or partially lacked clear data, such as articles that reported the THC content not clearly attributable to the herbal form of cannabis (including experimental cultivation) or that presented results together as a range of different concentrations or periods of time.

No divergent opinions in including or excluding studies were encountered between the reviewers, resulting in 21 studies that were eligible for the systematic review and meta-analysis.

*Data extraction* – This process was performed by two reviewers independently, resolving disagreement by discussion. Repetitions of data from serial publications were rejected, retaining the last update. Two authors were contacted for further information. All the eligible, included studies were written in the English language.

The following information was extracted from each included article and summarized:

- characteristics of the publication such as authors, study design, year and type of publication, first and second objectives, results and conclusion of the report;
- details of the study such as duration and place of conducting the research, number of samples, mean percentage and standard deviation of THC (or THC content per sample) per year, features of samples (age, geographic and cultivation origin, mode of sourcing, aspect, cannabis variety), features of chemical analyses (sampling, method, technique).

*Meta and Trend Analysis* – We meta-analyzed the results of the included studies by year to take into account the evident temporal trend in the mean % of THC. Given the heterogeneity between studies we adopted a random effects model [17]. We used the $I^2$ statistic to quantify the degree of heterogeneity among studies [18]. $I^2$ values of 50% or more indicate a substantial level of heterogeneity. Meta-regression using year as the covariate was performed to assess whether a temporal trend could explain the heterogeneity. To quantify the trend a Poisson regression was performed.

## RESULTS AND DISCUSSION

All the included studies [19-39] shown in the table below (Table **1**) were written in English and presented data on the THC content found in herbal cannabis samples in different years, depending on the date of the study.

Most were for an isolated geographic area and period of time and do not describe relevant information about the features (i.e. conservation status and age of the sample) of the analyzed herbal cannabis samples. The percentage of studies reporting the relevant sample details is shown in the bar chart (Fig. **2**) that portrays, for example: 13% of the included studies specify the origin of the sample, 8% do not; 11% indicates the mode of sample acquisition, 10% do not.

For published evidence on the temporal trend in potency, we carried out a meta-analysis of the extracted herbal cannabis data from studies in which the standard deviation around the mean THC value per year was available. Meta-analysis was performed by year on 75 total mean THC observations from 1970 to 2009 using the random effect model. Meta-regression was performed on the same dataset, using year as the covariate.

The results revealed great variability within studies ($I^2$ = 99.91%) and a significant association (from the meta-regression) (p value < 0.0001) between the mean THC in herbal cannabis and year (coef. 0.214; 95% CI = 0.163–0.266). A summary of the results from the meta-analysis and relative 95% CI per year are shown in Table **2** and Fig. (**3**).

[2]The PICOS (acronym of *Population, Interventions, Comparator, Outcomes, Study Design*) is a structured approach for framing relevant and precise questions, which are often complex and time-consuming, that can be answered in a systematic review.

[3]Systematic (IUPAC) name: (−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol. Abbreviation: THC. Formula: $C_{21}H_{30}O_2$.




**Fig. (1).** Flow diagram of study selection process concerning the THC content found in in herbal cannabis samples in a period of time.

The combined data from the 21 included studies indicated an increasing temporal trend in potency (Fig. **4**); the Poisson regression suggested an average increase in the mean THC value of 4.694% (95% CI 3.129–6.283). Of course, this is just an indication of the overall increase, but it is clear (from Fig. **4**) that this rise in mean THC seems to have been more rapid in the last decade.

Analysis of the trend (Tables **3** and **4**; Fig. **4**) according to geographical zone indicated a smaller increase in Europe (2.799%, 95% CI 1.157–4.467; significant at p = 0.001) compared to the rest of the world, almost totally represented by the U.S. (5.279%, 95% CI 3.590–6.996), but this may reflect the fact that the data from Europe started with a higher mean THC.

The European studies indicated a very high mean THC level in recent years with little variability around this mean, especially in The Netherlands; the cannabis potency phenomenon was, on the other hand, characterized by minor fluctuations and relative stability from 1975 to 1989 in other European countries such as Great Britain and Ireland; data from Greece and Denmark, although scarce, revealed a constantly low mean THC value while Italy, particularly the northern part, showed a clear increasing temporal trend.

No other information concerning Europe was obtained from the publications fulfilling the eligibility criteria for the present review; it must also be noted that the cannabis reports on governmental websites are the responsibility of single research groups in each country.

With regard to the rest of the countries (particularly U.S.A.), an evident rise in the mean THC content in herbal cannabis seizure samples from 1997 to 2009, with large variability around this mean value, was reported by the Mississippi University Project [40].

The results of this systematic review suggest that the herbal cannabis market is changing worldwide towards an increasing level of THC content. Further, this increase is not constant and does not exceed 5% globally. According to some [41] it would be right to admit a doubling of potency over the years, possibly due to the increased availability of intensively grown indoor herbal cannabis, but not that cannabis is 25 times stronger than it was a decade ago [4].

On the other hand it should be considered that data from the included studies could present an underestimation of the true mean THC value of commercial herbal cannabis because of the freshness and age of samples from harvesting, their composition before chemical analysis, and the sampling method for the analysis. It is actually well known that the THC content in cannabis can vary in relation to environmental factors such as light, temperature and the humidity during plant growth and sample storage, as well as being influenced by genetic features [42-45].

**Table 1. ID and Characteristics of Included Articles (n= 21); in All Cases the Design was Observational (Case Series) and the Language was English**

| ID | Authors | Year | Journals with Impact Factor | Other Publication/Other Type of Journals |
|---|---|---|---|---|
| 1 | Bertol E and Mari F [a] | 1980 | | Bulletin on Narcotics |
| 2 | Baker PB *et al.* [b] | 1980 | | Bulletin on Narcotics |
| 3 | Baker PB *et al.* [c] | 1982 | | Bulletin on Narcotics |
| 4 | Felby S and Nielsen E [d] | 1985 | | Bulletin on Narcotics |
| 5 | Pitts JE *et al.* [e] | 1990 | J Pharmacol | |
| 6 | Kaa E [f] | 1989 | Z Rechtsmed | |
| 7 | Stefanidou M *et al.* [g] | 2000 | Chem Pharm Bull | |
| 8 | Pijlman FT *et al.* [h] | 2005 | Addiction Biology | |
| 9 | Marshman JA *et al.* [i] | 1976 | | Bulletin on Narcotics |
| 10 | ElSohly MA ∗ [j] | 2009 | | Marijuana Potency Monitoring Project. Report 104 |
| 11 | Potter DJ *et al.* [k] | 2008 | J Forensic Sci | |
| 12 | Bone C and Waldron SJ [l] | 1997 | | Bulletin on Narcotics |
| 13 | - [m] | 2005 | | EMCDDA Statistical Bulletin |
| 14 | - [n] | 2006 | | EMCDDA Statistical Bulletin |
| 15 | - [o] | 2007 | | EMCDDA Statistical Bulletin |
| 16 | - [p] | 2008 | | EMCDDA Statistical Bulletin |
| 17 | - [q] | 2009 | | EMCDDA Statistical Bulletin |
| 18 | Lopez de Oliveira *et al.* [r] | 2008 | Forensic Toxicol | |
| 19 | Stefanidou M *et al.* [s] | 1998 | Forensic Science Intern | |
| 20 | Chiesa EP and Rondina RV [t] | 1973 | J Pharm Pharmac | |
| 21 | Licata M *et al.* ∗ [u] | 2005 | | Ann Ist Super Sanità |

∗ = Data updated in 2010 directly from the authors of the original article.




**Fig. (2).** Bar chart of samples features reported in percentage into the included studies.

The mean THC value could be limited due to the peculiarities of cannabis samples and to methodological differences between laboratories, even though the analytical techniques are the same worldwide, involving gas or liquid chromatography eventually coupled with mass spectrometry [46, 47].

[a] [19]; [b] [20]; [c] [21]; [d] [22]; [e] [23]; [f] [24]; [g] [25]; [h] [26]; [i] [27]; [j] [28]; [k] [29]; [l] [30]; [m] [31]; [n] [32]; [o] [33]; [p] [34]; [q] [35]; [r] [36]; [s] [37]; [t] [38]; [u] [39].

**Table 2. Results of Meta-Analysis on 75 Mean THC Observations from Studies in which the Standard Deviation Around the Mean THC Value Per Year was Available**

| Year Reported | Mean THC Content Per Year | 95% IC | Weight of Studies | Number of Studies | Number of Samples |
|---|---|---|---|---|---|
| **1970** | 0,93 | 0,615 - 1,245 | 1,36 | 1 | 28 |
| **1971** | 2,22 | 1,345 - 3,095 | 1,34 | 1 | 15 |
| **1972** | 1,17 | 0,753 – 1,587 | 1,35 | 1 | 34 |
| **1973** | 1,436 | 0,175 – 2,697 | 2,67 | 2 | 37 |
| **1974** | 1,27 | 0,949 – 1,591 | 1,36 | 1 | 67 |
| **1975** | 2,113 | 0,346 - 4,571 | 2,7 | 2 | 130 |
| **1976** | 2,371 | 0,322 – 4,42 | 4,04 | 3 | 150 |
| **1977** | 0,66 | 0,527 – 0,793 | 1,36 | 1 | 138 |
| **1978** | 2,408 | 0,281 – 4,534 | 2,71 | 2 | 212 |
| **1979** | 2,042 | 0,997 – 3,087 | 4,07 | 3 | 366 |
| **1980** | 3,149 | 0,955 – 5,343 | 2,7 | 2 | 197 |
| **1981** | 3,567 | 1,01 – 6,124 | 2,7 | 2 | 300 |
| **1982** | 3,04 | 2,832 – 3,248 | 1,36 | 1 | 486 |
| **1983** | 2,396 | 0,74 – 4,053 | 2,72 | 2 | 1283 |
| **1984** | 4,751 | 1,822 – 7,679 | 2,69 | 2 | 1099 |
| **1985** | 3,412 | 1,893 – 4,932 | 2,64 | 2 | 1563 |
| **1986** | 3,435 | 1,191 – 5,678 | 2,71 | 2 | 1569 |
| **1987** | 3,025 | 2,631 – 3,42 | 2,7 | 2 | 1701 |
| **1988** | 2,552 | 0,583 – 4,521 | 4,07 | 3 | 2234 |
| **1989** | 3,897 | 2,193 – 5,601 | 2,71 | 2 | 1321 |
| **1990** | 3,35 | 3,191 – 3,509 | 1,36 | 1 | 1263 |
| **1991** | 3 | 2,892 - 3,108 | 1,36 | 1 | 2507 |
| **1992** | 3,1 | 3,017 – 3,183 | 1,36 | 1 | 3540 |
| **1993** | 3,29 | 3,203 – 3,377 | 1,36 | 1 | 3353 |
| **1994** | 3,48 | 3,398 – 3,563 | 1,36 | 1 | 3278 |
| **1995** | 3,74 | 3,678 – 3,802 | 1,36 | 1 | 4732 |
| **1996** | 2,885 | 0,546 – 5,225 | 2,71 | 2 | 2457 |
| **1997** | 4,53 | 4,396 – 4,664 | 1,36 | 1 | 2455 |
| **1998** | 3,058 | 0,351 – 5,766 | 2,71 | 2 | 2293 |
| **1999** | 3,274 | 0,738 – 5,81 | 2,71 | 2 | 2671 |
| **2000** | 6,265 | 4,058 – 8,472 | 3,95 | 3 | 3225 |
| **2001** | 6,047 | 2,24 – 9,854 | 4,07 | 3 | 2884 |
| **2002** | 9,543 | 4,005 – 15,081 | 4,06 | 3 | 2596 |
| **2003** | 12,043 | 5,159 – 18,927 | 3,41 | 3 | 2636 |
| **2004** | 12,422 | 4,645 – 20,2 | 3,87 | 3 | 2760 |
| **2005** | 8,862 | 5,206 – 12,517 | 2,6 | 2 | 2985 |
| **2006** | 7,51 | 7,299 – 7,721 | 2,49 | 2 | 2870 |
| **2007** | 6,958 | 2,562 – 11,354 | 4,03 | 3 | 3118 |
| **2008** | 8,625 | 8,389 – 8,861 | 2,64 | 2 | 2752 |
| **2009** | 9,75 | 7,956 – 11,544 | 1,29 | 1 | 82 |




**Fig. (3).** Per-year meta-analysis graph showing the mean THC value with 95% CI.




**Fig. (4).** Time trend of the mean THC value for all samples and disaggregated by zone.

**Table 3. Data from All Included Studies Used for Time Trend Analysis**

| All Studies | | | | |
|---|---|---|---|---|
| **Place** | **Authors** | **Year** | **Mean %THC** | **Samples** |
| USA | El Sohly | 1970 | 0,930 | 28 |
| USA | El Sohly | 1971 | 2,220 | 15 |
| USA | El Sohly | 1972 | 1,170 | 34 |
| USA + Argentine | Chiesa *et al*. + El Sohly | 1973 | 1,383 | 61 |
| USA | El Sohly | 1974 | 1,270 | 67 |
| USA + UK | El Sohly + Baker *et al*. (1) | 1975 | 1,855 | 130 |
| USA + Jamaica + UK | El Sohly + Marshman *et al*. + Baker *et al*. | 1976 | 2,196 | 150 |
| USA | El Sohly | 1977 | 0,660 | 138 |
| USA + UK | El Sohly + Baker *et al*. (1) | 1978 | 2,210 | 212 |
| USA + UK + Italy | El Sohly + Baker *et al*. (2) + Bertol *et al*. | 1979 | 1,841 | 366 |
| USA + UK | El Sohly + Baker *et al*. (2) | 1980 | 2,560 | 197 |
| USA + UK | El Sohly + Baker *et al*. (2) | 1981 | 2,647 | 300 |
| USA | El Sohly | 1982 | 3,040 | 486 |
| USA + Denmark | El Sohly + Felby *et al*. | 1983 | 3,140 | 1283 |
| USA + UK + IR | El Sohly + Pittis *et al*. | 1984 | 3,400 | 1099 |
| USA + UK + IR | El Sohly + Pittis *et al*. | 1985 | 2,884 | 1563 |
| USA + UK + IR | El Sohly + Pittis *et al*. | 1986 | 2,390 | 1569 |
| USA + UK + IR | El Sohly + Pittis *et al*. | 1987 | 2,948 | 1701 |
| USA + UK + IR + Denmark | El Sohly | 1988 | 2,864 | 2234 |
| USA + UK + IR | El Sohly + Pittis *et al*. | 1989 | 3,125 | 1321 |
| USA | El Sohly | 1990 | 3,350 | 1263 |
| USA | El Sohly | 1991 | 3,000 | 2507 |
| USA | El Sohly | 1992 | 3,100 | 3540 |
| USA | El Sohly | 1993 | 3,290 | 3353 |
| USA | El Sohly | 1994 | 3,480 | 3278 |
| USA + UK | El Sohly + Bone *et al*. | 1995 | 3,740 | 4802 |
| USA + UK + Greece | El Sohly + Bone *et al*. + Stefanidou *et al*. | 1996 | 4,102 | 2532 |
| USA + UK | El Sohly + Bone *et al*. | 1997 | 4,694 | 2595 |
| USA + Greece | El Sohly + Stefanidou *et al*. | 1998 | 4,394 | 2293 |
| USA + Italy | El Sohly + Licata *et al*. | 1999 | 4,536 | 2671 |
| USA + Italy + The Netherlands | El Sohly + Licata *et al*. + Pijlman *et al*. | 2000 | 4,954 | 3225 |
| USA + Italy + The Netherlands | El Sohly + Licata *et al*. + Pijlman *et al*. | 2001 | 5,469 | 2884 |
| USA + Italy + The Netherlands | El Sohly + Licata *et al*. + Pijlman *et al*. | 2002 | 6,767 | 2596 |
| Usa + Europe + Italy + The Netherlands | El Sohly + EMCDDA + Licata *et al*. + Pijlman *et al*. | 2003 | 4,680 | 8748 |
| Usa + Europe + Italy + The Netherlands | El Sohly + EMCDDA + Licata *et al*. + Pijlman *et al*. | 2004 | 6,775 | 6080 |
| USA + Europe + Italy + UK | El Sohly + EMCDDA + Licata *et al*. + Potter *et al*. | 2005 | 7,048 | 6416 |
| USA + Europe + Italy | El Sohly + EMCDDA + Licata *et al*. | 2006 | 6,512 | 6902 |
| USA + Europe + Brazil + Italy | El Sohly + EMCDDA + Lopez *et al*. + Licat *et al*. | 2007 | 6,174 | 6810 |
| USA + Italy | El Sohly + Licata *et al*. | 2008 | 8,632 | 2752 |
| Italy | Licata *et al*. | 2009 | 9,750 | 82 |

**Table 4. Data from European Studies Used for Time Trend Analysis**

| Europe | | | | |
|---|---|---|---|---|
| **Place** | **Authors** | **Year** | **Mean %THC** | **Samples** |
| UK | Baker, *et al*. (1) | 1975 | 3,400 | 50 |
| UK | Baker, *et al*. (1) | 1976 | 3,800 | 50 |
| UK | Baker, *et al*. (1) | 1978 | 3,500 | 86 |
| UK + Italy | Baker, *et al*. (2) + Bertol *et al*. | 1979 | 2,099 | 146 |
| UK | Baker, *et al*. (2) | 1980 | 4,300 | 44 |
| UK | Baker, *et al*. (2) | 1981 | 4,900 | 41 |
| Denmark | Felby, *et al*. | 1983 | 1,550 | 76 |
| UK + IR | Pittis, *et al*. | 1984 | 6,300 | 33 |
| UK + IR | Pittis, *et al*. | 1985 | 4,500 | 23 |
| UK + IR | Pittis, *et al*. | 1986 | 4,600 | 55 |
| UK + IR | Pittis, *et al*. | 1987 | 3,500 | 24 |
| UK + IR + Denmark | Pittis *et al*. + Kaa *et al*. | 1988 | 1,024 | 444 |
| UK + IR | Pittis, *et al*. | 1989 | 4,800 | 49 |
| UK | Bone *et al*. | 1995 | 3,766 | 70 |
| UK + Greece | Bone *et al*. + Stefanidou *et al*. | 1996 | 4,793 | 111 |
| UK | Bone *et al*. | 1997 | 7,566 | 140 |
| Greece | Stefanidou, *et al*. | 1998 | 1,667 | 30 |
| Italy | Licata *et al*. | 1999 | 1,962 | 14 |
| Italy + The Netherlands | Licata *et al*. + Pijlman *et al*. | 2000 | 7,314 | 111 |
| Italy + The Netherlands | Licata *et al*. + Pijlman *et al*. | 2001 | 7,748 | 188 |
| Italy + The Netherlands | Licata *et al*. + Pijlman *et al*. | 2002 | 11,778 | 204 |
| Europe + Italy + The Netherlands | EMCDDA + Licata *et al*. + Pijlman *et al*. | 2003 | 4,040 | 6251 |
| Europe + Italy + The Netherlands | EMCDDA + Licata *et al*. + Pijlman *et al*. | 2004 | 6,538 | 3472 |
| Europe + UK + Italy | EMCDDA + Licata *et al*. + Potter *et al*. | 2005 | 6,944 | 3465 |
| Europe + Italy | EMCDDA + Licata *et al*. | 2006 | 5,807 | 4046 |
| Europe + Italy | EMCDDA + Licata *et al*. | 2007 | 4,581 | 3738 |
| Italy | Licata *et al*. | 2008 | 9,563 | 64 |
| Italy | Licata *et al*. | 2009 | 9,750 | 82 |

To overcome the methodological limits for cannabis samples, recommendations for the standardization of analytical procedures have recently been proposed by United Nations Office on Drugs and Crime [48]. We also hope for an alignment of the interested nations with regular monitoring of the cannabis market to enable constant tracking of the THC temporal trend in accordance with validated guidelines on sample classification, storage, sampling and analytical methods, and the data required from the analyses.

Systematic reviews and the meta-analysis of data from heterogeneous case series studies can be complex. On the other hand they are useful to outline the shape of a phenomenon, as in the case of cannabis, concerning an increasing temporal trend in the potency of this drug.

**Key Learning Objectives:**

- The cannabis market is the largest illicit drug market in terms of the global spread of cultivation, the volume of production and the number of consumers.
- The amount of the main active constituent of cannabis, $\Delta^9$-tetrahydrocannabinol ($\Delta^9$-THC), naturally depends on the influence that factors such as genotype, plant age and environment have on the biosynthesis of cannabinoids.
- The herbal form of cannabis (i.e. flowering tops and leaves of the plant, which are smoked like tobacco) is traditionally known to have a lower level of $\Delta^9$-THC (very rarely exceeding 5%) in comparison with other resin-type cannabis preparations such as hashish (generally up to 20%) and hash oil (sometimes even above 50%).
- Significantly higher THC concentrations in herbal cannabis were recently documented in the literature.
- The availability of a more THC-concentrated form of herbal cannabis could cause an increase in the total amount of THC consumed, with foreseeable consequences for public health.

**Future Research Questions:**

- The herbal cannabis market is changing toward an increasing tetrahydrocannabinol (THC) content, although published international data concerning the diffusion of such potent varieties and the level of increase in potency are poor: existing information on cannabis is fragmented, non-standardized and not always based on scientific evidence.
- Continuous, worldwide tracking of herbal cannabis's THC level in accordance with validated guidelines on sampling, sample classification, storage and analytical methods, and the data obtained from analysis, could allow countries interested in the monitoring of the cannabis market to pool their resources to greater effect.
- Clear information about drug potency could be useful for societal and political decisions relating to public health (i.e. health educational programmes for youth, prevention campaigns, prohibition measurements) and also for judicial verdicts concerning illegal traffic and for criminalistics.
- Scientific investigations on cannabis through genetic and chemical analyses could be undertaken to describe and explain the natural and/or artificial mechanisms behind the potency increase with the aim of controlling the drug market more effectively.

## ACKNOWLEDGEMENTS

We thank Prof. M. Chiarotti (Istituto di Medicina Legale, Università Cattolica del S. Cuore, Roma) for leading our work. This study was supported by grants from the National Department of Drug Politics and from the AGIS project n. JLS/2006//AGIS 231.

## CONFLICT OF INTEREST

This paper does not have duplicate publication problems, financial or other relationships that could give rise to conflicts of interest; further, the manuscript does not reproduce published material, illustrations or report sensitive personal information about identifiable persons.

## REFERENCES

[1] United Nations Office on Drugs and Crime [homepage on the internet]. World Drug Report 2009. 1.3 page 89. Available from www.unodc.org

[2] If marijuana is legal, will addiction rise? The New York Times, 19/7/2009.

[3] Report: Marijuana potency rises. USA Today, 6/12/2008.

[4] Cannabis: An apology. The Independent on Sunday. 18/3/2007.

[5] Cannabis: tough penalties on way after another change of mind. The Times, 4/4/2008.

[6] United Nations Office on Drugs and Crime [homepage on the internet]. World Drug Report 2006. Vol. 1, 2.3; pag. 172. Available from www.unodc.org

[7] European Monitoring Centre for Drugs and Drug Addiction. A Cannabis reader: global issues and local experiences [Monograph on the internet]. EMCDDA 2008. Available from www.emcdda.europa.eu

[8] Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 2006; 31: 2296–2303.

[9] Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in Cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53: 90–94.

[10] Rey JM, Tennant CC. Cannabis and mental health. BMJ 2002; 325: 1183–1184.

[11] Henry JA, Oldfield WLG, Kon OM. Comparing Cannabis with tobacco. BMJ 2003; 326: 942–943.

[12] King LA, Carpentier C, Griffiths P. Cannabis potency in Europe. Addiction 2005; 100: 884–886.

[13] United Nations Office on Drugs and Crime [homepage on the internet]. Terminology and Information on Drugs. II edition. 2003. Available from www.unodc.org

[14] McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008; 103: 1100-9.

[15] Higgins JPT, Green. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration [homepage on the internet], 2009. Available from www.cochrane-handbook.org.

[16] Liberati A, Altman DG, Tetzlaff J, *et al*. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.

[17] Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trias 1986; 7: 177-88.

[18] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.

[19] Bertol E, Mari F. Observation on cannabinoid content in Cannabis *sativa* L. grown in Tuscany, Italy. Bull Narcotics 1980; 4: 55-60.

[20] Baker PB, Bagon KR, Gough TA. Variation in the THC content in illicitly imported Cannabis products. Bull Narcotics 1980; 4: 47-54.

[21] Baker PB, Gough TA, Johncock SIM, Taylor BJ, Wyles LT. Variation in the THC content in illicitly imported Cannabis products: part II. Bull Narcotics 1982; 3: 101-8.

[22] Felby S, Nielsen E. Cannabinoid content of Cannabis grown on the Danish Island of Bornholm. Bull Narcotics 1985; 4: 87-94.

[23] Pitts JE, O'Neil PJ, Leggo KP. Variation in the THC content of illicitly imported Cannabis product 1984–1989. J Pharmacol 1990; 2: 817-20.

[24] Kaa E. Cannabis plants illicitly grown in Jutland (Denmark). Z Rechtsmed 1989; 102: 367-75.

[25] Stefandiou M, Athanaselis S, Alevisopoulos G, Papoutsis J, Koutselinis A. Delta-9- tetrahydrocannabinol content in Cannabis plants of Greek origin. Chem Pharm Bull 2000; 48: 743-5.

[26] Pijlman FT, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ. Strong increase in total delta-THC in Cannabis preparations sold in Dutch coffee shops. Addict Biol 2005; 10: 171-80.

[27] Marshman JA, Popham RE, Yawney CD. A note on the cannabinoid content of Jamaican ganja. Bull Narcotics 1976; 28: 63-8.

[28] El Sohly MA. Quarterly Report. Potency Monitoring Project. Report 104. December 16, 2008 through March 15, 2009.

[29] Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in Cannabis in England in 2005: Implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53: 90-4.

[30] Bone C, Waldron SJ. New trends in illicit Cannabis cultivation in the United Kingdom of Great Britain and Northern Ireland. Bull Narcotics 1997; 1: 117-28.

[31] European Monitoring Centre for Drugs and Drug Addiction [homepage on the internet]. Statistical Bulletin 2005, Table PPP-5 part (i). Available from www.emcdda.europa.eu

[32] European Monitoring Centre for Drugs and Drug Addiction [homepage on the internet]. Statistical Bulletin 2006, Table PPP-5 part (i). Available from www.emcdda.europa.eu

[33] European Monitoring Centre for Drugs and Drug Addiction [homepage on the internet]. Statistical Bulletin 2007, Table PPP-5 part (i). Available from www.emcdda.europa.eu

[34] European Monitoring Centre for Drugs and Drug Addiction [homepage on the internet]. Statistical Bulletin 2008, Table PPP-5 part (i). Available from www.emcdda.europa.eu

[35] European Monitoring Centre for Drugs and Drug Addiction [homepage on the internet]. Statistical Bulletin 2009, Table PPP-5 part (i). Available from www.emcdda.europa.eu

[36] Lopez de Oliveira G, Voloch MH, Sztulman GB, *et al*. Cannabinoid content in Cannabis products seized in Sao Paulo, Brasil, 2006–2007. Forensic Toxicol 2008; 26: 31-5.

[37] Stefanidou M, Athanaselis S, Alevisopoulos G, Papoutsis J, Koutselinis A. The cannabinoid content of marijuana samples seized in Greece and its forensic application. Forensic Sci Int 1998; 95: 153-62.

[38] Chiesa EP, Rondina RVD. Chemical composition and potential activity of Argentine marijuana. J Pharm Pharmacol 1973; 25: 953-6.

[39] Licata M, Verri P, Beduschi G. Delta-9-THC content in illicit Cannabis products over the period 1997–2004. Ann Ist Super Sanità 2005; 41: 483–485.

[40] Mehmedic Z, Chandra S, Slade D, *et al*. Potency trends of Δ9-THC and other cannabinoids in confiscated Cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55: 1209-17.

[41] Ben Goldacre. Bad Science. London: Fourth Estate; 2008.

[42] Taylor BJ, Neal JD, Gough TA. The physical and chemical features of Cannabis plants grown in the United Kingdom of Great Britain and Northern Ireland from seeds of known origin – part III: third and fourth generation studies. Bull Narcotics, United Nations Publ 1985; XXXVII: 75-81.

[43] Pitts JE, Neal TA. Some features of Cannabis plants grown in the United Kingdom from seeds of known origin. J Pharm Pharmacol 1992; 44: 947-51.

[44] Avico U, Pacifici R, Zuccaro P. Variations of tetrahydrocannabinol content in, Cannabis plants to distinguish the fibre-type from the drug-type plants. Bull Narcotics, United Nations Publ 1985; XXXVII: 61-6.

[45] Fetterman PS, Keith ES, Waller CW, Guerrero O, Doorenbos NJ, Quimby MW. Mississippi-grown *Cannabis sativa* L. Preliminary observation on chemical definition of phenotype and variations in tetrahydrocannabinol content versus age, sex and plant parts. J Pharm Sci 1971; 60: 1246-9.

[46] Stolker AAM, van Schoonhoven J, de Vries AJ, *et al*. Determination of cannabinoids in Cannabis products using liquid chromatography-ion trap mass spectrometry. J Chromatogr A 2004; 1058: 143-51.

[47] Gambaro V, Dell'Acqua L, Farè F, Froldi R, Saligari E, Tassoni G. Determination of primary active constituents in Cannabis preparations by high-resolution gas chromatography/flame ionization detection and high performance liquid chromatography/UV detection. Anal Chim Acta 2002; 468: 245-54.

[48] United Nations Office on Drugs and Crime [homepage on the internet]. Recommended methods for the identification and analysis of Cannabis and Cannabis products. Manual for use by national drug analysis laboratories. (ST/NAR/ 40) 2009. Available from www.unodc.org.

Received: September 1, 2011 Revised: October 27, 2011 Accepted: October 28, 2011